Lytix Biopharma AS   Report issue

For profit Phase 1 Phase 2
Founded: Tromso Norway (2003)

Organization Overview

First Clinical Trial
2010
NCT01058616
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Lytix Biopharma AS

Active Ingredients

Drugs in Phase 2 Trials (4)

autologous tumor infiltrating lymphocytes (1 trial)

ltx-109 (3 trials)

ltx-315 (5 trials)

pembrolizumab (keytruda) (2 trials)

Drugs in Phase 1 Trials (1)

ipilimumab (yervoy) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Carcinoma (Phase 1)

Cellulitis (Phase 2)

Communicable Diseases (Phase 2)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Eczema (Phase 2)

Hypersensitivity (Phase 2)

Impetigo (Phase 2)

Infections (Phase 2)

Sarcoma (Phase 2)

Skin Diseases (Phase 2)

Skin Diseases, Infectious (Phase 2)

Triple Negative Breast Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 8
  • # of Trial APIs: 5